Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05201469 · ClinicalTrials.gov registry record · Phase 2
VIBRANT: VIB4920 for Active Lupus Nephritis
A Phase 2 study of Lupus Nephritis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
- 17
- Study locations
NCT05201469 is a Phase 2 study of Lupus Nephritis that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 74 participants, below the 308-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (76% lower). The trial reports 17 study locations across 11 states.
The verdict
NCT05201469, a Phase 2 study of Lupus Nephritis, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).
Conditions Studied
Interventions
- DRUG VIB4920
- DRUG Placebo for VIB4920
Study Locations (17)
California
- University of California San Diego School of Medicine: Division of Rheumatology, Allergy and Immunology - La Jolla
- UCLA Medical Center: Division of Rheumatology - Los Angeles
- of California, Irvine School of Medicine Division of Rheumatology - Orange
- University of California San Francisco School of Medicine: Lupus Clinic and Rheumatology Clinical Research Center - San Francisco
New York
- Feinstein Institute for Medical Research: Center for Autoimmune and Musculoskeletal Diseases - Manhasset
- Hospital for Special Surgery, New York: Division of Rheumatology - New York
- Columbia University Medical Center: Department of Medicine, Division of Rheumatology - New York
Pennsylvania
- Penn State Health Milton S. Hershey Medical Center: Division of Rheumatology - Hershey
- Temple University, Lewis Katz School of Medicine, Department of Medicine: Nephrology - Philadelphia
Colorado
- University of Colorado School of Medicine: Division of Rheumatology - Aurora
Connecticut
- Yale University School of Medicine: Section of Rheumatology - New Haven
Florida
- University of Miami Miller School of Medicine: Nephrology & Hypertension Division - Miami
Georgia
- Emory University School of Medicine: Division of Rheumatology - Atlanta
Illinois
- University of Chicago, Department of Medicine: Rheumatology - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2022-05-16 |
| Est. Completion | 2027-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05201469
The ClinicalTrials.gov registry entry for NCT05201469 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 308-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (76% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lupus Nephritis appearing as the primary indexed condition, and to 2 interventions - of which VIB4920 is the first listed.
NCT05201469 reports 17 study locations spanning 11 distinct geographic areas - top geographies include California, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05201469 about?
NCT05201469 is a clinical study titled "VIBRANT: VIB4920 for Active Lupus Nephritis". This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).
What is the current status of trial NCT05201469?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2022-05-16. Estimated completion is 2027-03.
What conditions does trial NCT05201469 study?
This clinical trial studies the following conditions: Lupus Nephritis.
What interventions are being tested in trial NCT05201469?
The interventions under investigation include: VIB4920 (DRUG), Placebo for VIB4920 (DRUG).
Who is sponsoring clinical trial NCT05201469?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05201469 being conducted?
This trial has 17 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Nephritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
RECRUITING · Phase 2
-
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
RECRUITING · Phase 2
-
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
RECRUITING · Phase 2
-
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
RECRUITING · Phase 2
-
Daratumumab to Treat Active Lupus Nephritis
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.